icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Safety and Efficacy of Twice Daily versus Every 8 Hour Telaprevir with Peginterferon/Ribavirin in Patients with Cirrhosis
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
Yves Horsmans,1 Robert S Brown Jr,2 Maria Buti,3 Kosh Agarwal,4 William Sievert,5 Ewa Janczewska,6 Stefan Zeuzem,7 Lisa Nyberg,8 Christophe Hezode,9 Mario Rizzetto,10 Raymundo Parana,11Sandra De Meyer,12 Ralph De Masi,13 Donghan Luo,13 James Witek13 1Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; 2Columbia University College of Physicians and Surgeons, New York, NY, USA; 3Hospital Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain; 4Kings College Hospital, London, UK; 5Monash Medical Centre and Monash University, Melbourne, Australia; 6Outpatients Clinic for Hepatology, Myslowice, Poland; 7Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 8Kaiser Permanente, San Diego, CA, USA; 9Hôpital Henri Mondor, Créteil, France; 10University of Torino, Torino, Italy; 11Medical School, Federal University of Bahia, Bahia, Brazil; 12Janssen Infectious Diseases BVBA, Beerse, Belgium; 13Janssen Research & Development LLC, Titusville, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif